Please upgrade your browser.
Research findings, 'Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient,' are discussed in a new report. In this recently published article, scientists in the United States conducted a study "To determine whether iatrogenic immunosuppression used after transplantation infers a poor prognosis of renal cell carcinoma (RCC) as natural negative immune regulators have been associated with decreased cancer-specific survival from RCC. All patients with a solid organ transplant who underwent radical nephrectomy or nephron-sparing surgery for nonhereditary sporadic RCC from 1970 to 2003 were identified and retrospectively reviewed."
In an editorial accompanying the data in Lancet Oncology, Steven E. Nissen, MD, of the department of medicine, Cleveland Clinic, called the meta-analysis disturbing and proactive.
Aveo Pharmaceuticals Inc., a Cambridge biotech firm, said the European Medicines Agency has granted orphan status to one of its experimental drugs.
The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also includes methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.
Background: Multiple new therapies are now approved for patients (pts) with advanced RCC. As these agents enter widespread use, their perceived toxicities may differ from those reported in the literature and limit treatment duration and clinical outcomes. Patient reporting of toxicities may more accurately identify side effects most relevant to patients.
An Acreage couple have filed a lawsuit against Pratt & Whitney, blaming the defense contractor for the wife's kidney cancer amid a state probe of an unsolved cancer cluster in their community.
Doctors should monitor patients taking bevacizumab (Avastin), researchers say.
For months now, the Food and Drug Administration has been trying novel ways of encouraging drug makers to develop drugs for rare diseases.
We have received many positive comments about the exhibits attendees not only appreciated the variety of topics but noted how nice it was to talk with each of you you were all so welcoming and responded so well to the various questions and concerns of the survivors. --Linda L. Rohret, M.A., R.H.Ed
Semafore Pharmaceuticals Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
|Powered by NeonCRM|